On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €2
Sanifit has raised €72.2 million ($80.9m) in Spain’s largest private biotech fundraiser to finance phase 3 clinical development of its rare disease drug SNF472.
Spanish biotech Sanifit is targeting calcification disorders, and says it could have a potential multi-billion dollar treatment in two kidney failure indications.